242 related articles for article (PubMed ID: 19176207)
1. Myeloid growth factors.
Crawford J; Armitage J; Balducci L; Bennett C; Blayney DW; Cataland SR; Dale DC; Demetri GD; Erba HP; Foran J; Freifeld AG; Goemann M; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; Michaud LB; Miyata SC; Tallman MS; Vadhan-Raj S; Westervelt P; Wong MK;
J Natl Compr Canc Netw; 2009 Jan; 7(1):64-83. PubMed ID: 19176207
[No Abstract] [Full Text] [Related]
2. Myeloid growth factors clinical practice guidelines in oncology.
Crawford J; Althaus B; Armitage J; Blayney DW; Cataland S; Dale DC; Demetri GD; Foran J; Heaney ML; Htoy S; Kloth DD; Lyman GH; Michaud L; Motl S; Vadhan-Raj S; Wong MK;
J Natl Compr Canc Netw; 2005 Jul; 3(4):540-55. PubMed ID: 16038645
[No Abstract] [Full Text] [Related]
3. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia.
Stull DM; Bilmes R; Kim H; Fichtl R
Am J Health Syst Pharm; 2005 Jan; 62(1):83-7. PubMed ID: 15658078
[No Abstract] [Full Text] [Related]
4. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
Gómez Raposo C; Pinto Marín A; González Barón M
Clin Transl Oncol; 2006 Oct; 8(10):729-34. PubMed ID: 17074671
[TBL] [Abstract][Full Text] [Related]
5. ESMO recommendations for the application of hematopoietic growth factors.
Greil R; Jost LM;
Ann Oncol; 2005; 16 Suppl 1():i80-2. PubMed ID: 15888768
[No Abstract] [Full Text] [Related]
6. Hematopoietic growth factors for chemotherapy-induced neutropenia.
Yalçin S
Cancer Invest; 1999; 17(7):555-6. PubMed ID: 10518202
[No Abstract] [Full Text] [Related]
7. Interactive discussion on chemotherapy-related adverse events.
Adams VR; Lyman GH
Pharmacotherapy; 2000 Jul; 20(7 Pt 2):121S-125S. PubMed ID: 10905688
[No Abstract] [Full Text] [Related]
8. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
9. The use of growth factors with antibiotics in the setting of neutropenic fever.
Hussein AM; Elkordy M; Peters WP
Am J Med; 1996 Jan; 100(1):15-6. PubMed ID: 8579081
[No Abstract] [Full Text] [Related]
10. Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor.
Mucenski JW; Shogan JE
J Manag Care Pharm; 2003; 9(2 Suppl):10-4. PubMed ID: 14613339
[TBL] [Abstract][Full Text] [Related]
11. The role of myeloid growth factors in acute leukemia.
Wadleigh M; Stone RM
J Natl Compr Canc Netw; 2009 Jan; 7(1):84-91. PubMed ID: 19176208
[TBL] [Abstract][Full Text] [Related]
12. [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children].
Balwierz W; Moryl-Bujakowska A; Balwierz A; Pawińska K
Przegl Lek; 2006; 63(1):1-6. PubMed ID: 16892890
[TBL] [Abstract][Full Text] [Related]
13. Comparison of low-dose versus standard-dose colony stimulating factor in patients with chemotherapy-induced febrile neutropenia.
Burney IA; Salam A; Jat AA; Iqbal MP; Siddiqui T; Khan MA; Smego RA
Oncology; 2003; 65(3):283-4. PubMed ID: 14657603
[No Abstract] [Full Text] [Related]
14. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
[TBL] [Abstract][Full Text] [Related]
15. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors.
Ozer H
Curr Opin Hematol; 1996 Jan; 3(1):3-10. PubMed ID: 9372045
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
[TBL] [Abstract][Full Text] [Related]
17. Towards improved cancer therapy using subcutaneously administered hemopoietic colony stimulating factors.
Morstyn G; Sheridan W; Lieschke G; Cebon J; Layton J; Fox R
Prog Clin Biol Res; 1990; 354B():29-36. PubMed ID: 1700441
[No Abstract] [Full Text] [Related]
18. Colony-stimulating factors for febrile neutropenia during cancer therapy.
Bennett CL; Djulbegovic B; Norris LB; Armitage JO
N Engl J Med; 2013 Mar; 368(12):1131-9. PubMed ID: 23514290
[TBL] [Abstract][Full Text] [Related]
19. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
Crawford J
Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
[TBL] [Abstract][Full Text] [Related]
20. Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia.
Freyer G; Ligneau B; Trillet-Lenoir V
Int J Antimicrob Agents; 1998 Apr; 10(1):3-9. PubMed ID: 9624538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
